Gilead Sciences, Inc.'s Stock Analysis

Gilead Sciences Issues $3 Billion in Senior Notes

Gilead Sciences, Inc. has entered into an Eleventh Supplemental Indenture related to the issuance of $3 billion in Senior Notes. This includes $500 million in 4.250% notes due 2028, $1 billion in 4.400% notes due 2029, $1 billion in 4.600% notes due 2031, and $500 million in 4.900% notes due 2034. The interest on these notes will be paid semi-annually, and the proceeds will be used for general corporate purposes, including potential acquisitions and investments.

The Company has established certain restrictions under the Base Indenture and the Eleventh Supplemental Indenture, which limit its ability to incur secured debt and engage in significant transactions without adhering to specific conditions. Additionally, the Company may redeem the notes at applicable prices at any time. The offering was facilitated through an underwriting agreement with Barclays Capital Inc., BofA Securities, Inc., and Citigroup Global Markets Inc.

May 20, 2026 16:15:36

Gilead Sciences Reports First Quarter 2026 Financial Results

Gilead Sciences reported a 4% increase in total revenues for the first quarter of 2026, reaching $7.0 billion, driven primarily by higher sales of HIV products and other therapeutics. Product sales excluding Veklury rose 8% year-over-year to $6.8 billion, with significant contributions from Biktarvy and Descovy. Diluted earnings per share increased to $1.61, up from $1.04 in the prior year, while non-GAAP diluted EPS was reported at $2.03, compared to $1.81 in the same period last year. The company also reported a decrease in cash and cash equivalents to $8.6 billion, attributed to debt repayments and dividend payments, despite generating $2.5 billion in operating cash flow.

In operational updates, Gilead announced the acceptance of a New Drug Application for a new HIV treatment and highlighted the completion of several strategic acquisitions aimed at enhancing its oncology and inflammation portfolios. The company declared a quarterly dividend of $0.82 per share, payable on June 29, 2026. Gilead's guidance for the full year 2026 reflects a reduction in earnings per share expectations due to anticipated acquisition-related charges. Overall, Gilead is focusing on expanding its product offerings and pipeline while managing costs and investments in research and development.

May 07, 2026 16:03:01

Gilead Sciences Annual Meeting Results and Shareholder Votes

The 2026 annual meeting of Gilead Sciences stockholders took place on April 30, 2026, with a quorum achieved as 1,130,179,690 of the 1,241,222,013 shares entitled to vote were represented. Shareholders elected nine directors for the upcoming year and ratified Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2026.

Additionally, stockholders approved the advisory compensation of Named Executive Officers and the amended 2022 Equity Incentive Plan. However, proposals for an independent Board Chair policy and reports on patent exclusivities and ESG metrics were not approved by shareholders.

May 04, 2026 16:05:56

Gilead Completes Acquisition of Arcellx for $7.8 Billion

Gilead Sciences, Inc. has completed its acquisition of Arcellx, Inc. for $115 per share in cash, along with a contingent value right (CVR) of $5 per share, totaling an implied equity value of approximately $7.8 billion. This acquisition, which consolidates ownership of the investigational CAR T-cell therapy anitocabtagene autoleucel (anito-cel), positions Gilead to streamline development and maximize the potential of this product for treating multiple myeloma. Following the completion of the tender offer and merger, Arcellx has become a wholly owned subsidiary of Gilead, and its common stock will be delisted from Nasdaq.

The transaction is expected to impact Gilead’s earnings per share, reducing GAAP and non-GAAP diluted EPS by approximately $5.57 to $5.67 in 2026. Although the acquisition is anticipated to be modestly dilutive to earnings in 2026 and 2027, it is expected to become accretive in 2028 and beyond, contingent on FDA approval of anito-cel. Gilead’s investment in Arcellx aligns with its strategy to enhance its oncology portfolio and leverage its global capabilities to advance cancer treatment.

Apr 28, 2026 08:56:25

Gilead Sciences Announces Merger Agreement with Arcellx, Inc.

Gilead Sciences, Inc. has entered into a Merger Agreement with Arcellx, Inc., under which Gilead's subsidiary will commence a tender offer to acquire all outstanding shares of Arcellx for $115.00 per share in cash, along with a contingent value right (CVR) that may provide an additional $5.00 per share upon achieving certain sales milestones of Arcellx's product. The tender offer will remain open for at least 20 business days and is subject to customary conditions, including the tender of a majority of shares and regulatory approvals.

Additionally, Gilead has secured support agreements from key stakeholders of Arcellx, representing approximately 10.3% of outstanding shares, committing to tender their shares and support the merger. The agreement includes a termination fee of $260 million payable to Gilead if Arcellx accepts a superior offer. The transaction is contingent upon various customary conditions, including regulatory approvals and the absence of legal prohibitions against the merger.

Feb 23, 2026 06:46:27

Gilead Sciences Reports 2025 Financial Results and Product Sales

Gilead Sciences reported total revenues of $29.4 billion for the full year 2025, an increase of 2% compared to 2024. Product sales, excluding Veklury, rose 4% to $28.0 billion, primarily driven by higher sales of HIV and Liver Disease products. The company noted a diluted earnings per share (EPS) of $6.78 for the full year, up from $0.38 in 2024, due to lower research and development expenses, higher revenues, and reduced selling, general, and administrative costs. The company also generated $3.3 billion in operating cash flow during the fourth quarter of 2025 and had $10.6 billion in cash and equivalents at year-end.

For the fourth quarter of 2025, Gilead's total revenues increased by 5% to $7.9 billion, driven by higher sales of HIV and Liver Disease products, although Veklury sales decreased significantly. The company reported a diluted EPS of $1.74 for the quarter, up from $1.42 in the same period in 2024. Notable product sales included Biktarvy, which increased by 5% to $4.0 billion, and Descovy, which saw a 33% increase to $819 million. The company also declared a quarterly dividend of $0.82 per share, payable on March 30, 2026, indicating ongoing shareholder returns.

Feb 10, 2026 16:02:13

Gilead Sciences Announces Departure of General Counsel Deborah Telman

Gilead Sciences, Inc. announced that Deborah H. Telman will leave her position as Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025. Her employment with the company will officially end later in December.

This leadership change may impact the company's corporate governance and legal strategies. Investors may want to monitor how this transition affects Gilead's operations and overall business direction.

Nov 19, 2025 08:30:34

Gilead Sciences Reports Q3 2025 Financial Results and Updates

Gilead Sciences announced its financial results for the third quarter of 2025, reporting total revenues of $7.8 billion, a 3% increase from the same period in 2024. Product sales, excluding Veklury, rose by 4% to $7.1 billion, driven by higher sales of HIV products and Livdelzi, while overall product sales saw a decrease of 2%. Diluted earnings per share increased to $2.43 compared to $1.00 in the prior year, primarily due to the absence of a significant prior year impairment charge and increased other revenues.

Key product sales included Biktarvy, which grew 6% to $3.7 billion, and Descovy, which saw a 20% increase to $701 million. However, Veklury sales dropped 60% to $277 million, reflecting lower COVID-19 hospitalization rates. Gilead also reported a cash position of $9.4 billion as of September 30, 2025, and generated $4.1 billion in operating cash flow during the quarter. The company declared a quarterly dividend of $0.79 per share, payable on December 30, 2025, and announced plans for significant investments in U.S. manufacturing and development.

Oct 30, 2025 16:04:07

Gilead Settles Patent Disputes, Delaying Generic Biktarvy Entry

Gilead Sciences has reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigations concerning Biktarvy, a medication used to treat HIV. These agreements prevent the entry of generic versions of Biktarvy in the United States before April 1, 2036, securing the company's market exclusivity for its product containing bictegravir, emtricitabine, and tenofovir alafenamide.

The settlements are subject to standard acceleration provisions. This development may impact Gilead's financial performance and market position, as the agreements help maintain the company's revenue stream from Biktarvy by delaying competition from generic manufacturers.

Oct 06, 2025 08:17:11

Gilead Sciences Appoints New Senior Vice President of Controllership

Gilead Sciences has appointed Erin Burkhart as Senior Vice President, Controllership, and principal accounting officer, effective September 22, 2025. Burkhart, who is 46 years old, has been with BioMarin Pharmaceutical Inc. as Group Vice President and Chief Accounting Officer since May 2022 and has held various accounting and finance roles at Eli Lilly and Company from 2014 to 2022.

Burkhart will succeed Diane E. Wilfong, who is stepping down from her role as interim Controller and principal accounting officer on the same date. Burkhart is a licensed certified public accountant and holds a Bachelor of Science in Accounting from Butler University.

Aug 14, 2025 16:08:22